Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately
MWN-AI** Summary
Shareholders of Corcept Therapeutics (NASDAQ: CORT) who experienced financial losses amidst the company's recent challenges are encouraged to reach out to Wolf Haldenstein Adler Freeman & Herz LLP. A securities class action lawsuit has been initiated on behalf of investors who bought or otherwise acquired Corcept's securities between October 31, 2024, and December 30, 2025. Investors must register by April 21, 2026, to act as lead plaintiffs in the case.
The lawsuit accuses Corcept's leadership of issuing materially false and misleading statements regarding the company's drug, relacorilant, particularly in the context of its New Drug Application (NDA) submitted to the FDA. The defendants purportedly exaggerated the strength and support of clinical trials for relacorilant while downplaying risks associated with its approval. Allegedly, they presented communications with the FDA as favorable, indicating no anticipated obstacles to approval. However, it has come to light that the FDA expressed serious concerns regarding the adequacy of evidence supporting the NDA.
This situation has resulted in significant uncertainty for investors, as the integrity of the company’s business operations and future prospects has come under scrutiny. Wolf Haldenstein, a reputable firm with a long history in securities litigation, is dedicated to championing the rights of investors. Their experienced team is actively seeking to hold accountable those responsible for any financial misconduct.
Affected investors are urged to reach out to Wolf Haldenstein for further assistance, whether they need to register for the lawsuit or wish to contribute information related to the case. The firm can be contacted via phone at (800) 575-0735 or (212) 545-4774 or via email at classmember@whafh.com.
MWN-AI** Analysis
Shareholders of Corcept Therapeutics (NASDAQ: CORT) who have experienced financial losses should take immediate action by contacting Wolf Haldenstein Adler Freeman & Herz LLP. This prominent law firm has initiated a securities class action lawsuit on behalf of investors who acquired Corcept securities between October 31, 2024, and December 30, 2025. The firm is poised to provide legal support to those who claim to have suffered due to misleading statements from the company's leadership regarding the viability of its new drug candidate, relacorilant.
The allegations point to serious issues concerning Corcept’s transparency with its investors. Specifically, claims have emerged that the company overstated the strength of its clinical trials, portraying them as robust evidence for FDA approval. Moreover, it appears that Corcept’s representatives misled investors about their confidence in the drug’s regulatory prospects, despite receiving indications from the FDA that significant concerns regarding the clinical evidence existed. This lack of honesty can have far-reaching implications for shareholders, as it artificially inflated the stock price and created undue optimism around the company's performance.
Potential lead plaintiffs have until April 21, 2026, to step forward as part of this class action, emphasizing the urgency for affected investors to act promptly. Wolf Haldenstein has a long-standing reputation for advocating for investors’ rights, making them an ideal partner for anyone looking to address their grievances.
Investors who have incurred losses should contact the firm directly to discuss their options and potentially join the class action. By doing so, they may receive compensation for their financial setbacks and hold Corcept accountable for its actions. Don't miss this opportunity to protect your rights as an investor.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Lead Plaintiff Deadline is April 21, 2026
NEW YORK, March 24, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed against on behalf of all persons and entities that purchased or otherwise Corcept Therapeutics Incorporated (NASDAQ: CORT) ("Corcept" or the 'Company") securities between October 31, 2024 and December 30, 2025, both dates inclusive (the "Class Period"). Investors have until April 21, 2026, to seek appointments as lead plaintiff.
PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION
Corcept Case Details
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
- Defendants overstated the strength of the clinical trials supporting relacorilant by representing them as "powerful support" for Corcept's New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA");
- Defendants falsely conveyed confidence in relacorilant's regulatory prospects by claiming they had communicated with the FDA, foresaw no impediments to approval, and repeatedly told investors that "relacorilant is approaching approval," when, in fact, the FDA had repeatedly raised concerns regarding the adequacy of the clinical evidence supporting the NDA; and
- As a result of the foregoing, Defendants failed to disclose the known and material risk that Corcept's relacorilant NDA would not be approved, rendering their statements about the Company's business, operations, and prospects materially false and misleading at all relevant times.
Investors who suffered losses have until April 21, 2026 to seek appointment as lead plaintiff.
Why Wolf Haldenstein Adler Freeman & Herz LLP?:
This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.
We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.
Contact:
- Phone: (800) 575-0735 or (212) 545-4774
- Email: classmember@whafh.com
- Contact Person: Gregory Stone, Director of Case and Financial Analysis
Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Wolf Haldenstein Adler Freeman & Herz LLP
FAQ**
What specific misleading statements did Corcept Therapeutics Incorporated (CORT) allegedly make regarding the clinical trials for relacorilant, which may have led to financial losses for shareholders?
How did the alleged failure to disclose risks related to Corcept Therapeutics Incorporated (CORT) impact the stock's performance during the class period of October 31, 2024, to December 30, 2025?
In what ways can affected investors of Corcept Therapeutics Incorporated (CORT) leverage Wolf Haldenstein’s legal expertise to pursue claims for the losses they experienced?
What steps should shareholders of Corcept Therapeutics Incorporated (CORT) take by the April 21, 2026 deadline to seek appointment as lead plaintiff in the ongoing class action lawsuit?
**MWN-AI FAQ is based on asking OpenAI questions about Corcept Therapeutics Incorporated (NASDAQ: CORT).
NASDAQ: CORT
CORT Trading
-1.48% G/L:
$38.18 Last:
611,552 Volume:
$38.09 Open:
